Taysha Corp (TSHA) Long-Term Debt to Capital Ratio

This Taysha Gene Therapies (TSHA) trading chart highlights the impact of positive Rett syndrome therapy trial results, with the indicator standing at 0.15. The business focuses on treating rare CNS pathologies, seeking to accelerate the launch of innovations through special regulatory programs. The operating model relies on outsourcing, with vector creation and the conduct of research fully delegated to external CMO and CRO partners.

This indicator compares liabilities with a maturity of more than one year to equity, measuring the degree of financial leverage and the resilience of the balance sheet structure. The trend of the long-term debt-to-equity ratio is critically important for Taysha Gene Therapies (TSHA), as prolonged gene therapy clinical trials require significant funding before patents transform into a stable cash generator.